New drug SLN12140 aims to control kidney disease in IgA nephropathy patients

NCT ID NCT07553494

Not yet recruiting Disease control Sponsor: Linno Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests SLN12140, an experimental drug, in 48 adults with IgA nephropathy whose disease is not well-controlled by standard treatments. Participants receive different doses of SLN12140 or a placebo for 36 weeks, then all can receive the drug for another year. The main goal is to see if SLN12140 reduces protein in the urine, a sign of kidney damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SLN12140
What this could lead to: If successful, this could point toward a new treatment option for IgA nephropathy patients who don't respond well to current standard therapies.
What could go wrong: This is an early Phase 2 study with only 48 participants, so results may not apply broadly. The drug may not improve kidney function or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY (IGAN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

IgA glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IGA NEPHROPATHY (IGAN)

Contacts and locations

Locations

Beijing University 1st hospital

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.